AbbVie gets FDA approval for Hepatitis C combination therapy

AbbVie gets FDA approval for Hepatitis C combination therapy Daklinza plus sofosbuvir resulted in 90% SVR12 in treatment-naive and 86% in treatment-experienced chronic HCV genotype 3 patients. Most people infected with HCV have no symptoms of the disease until liver … Continue reading

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral … This submission affirms the company's commitment to seeking access to curative* therapy for patients living with chronic HCV infection (*curative is defined as when the virus is no longer … Continue reading

AbbVie to Present New Data from Hepatitis C Clinical Development Program at

AbbVie to Present New Data from Hepatitis C Clinical Development Program at … VIEKIRAX and EXVIERA are not recommended as monotherapy and should be used in combination with other medicinal products for the treatment of hepatitis C infection. Pregnancy and … Continue reading